Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Noelle Jung, Thorben Hennig, Leo Ruhnke, Joris Maximillian Frenz, Maithreyan Kuppusamy, Robert Autry, Lanying Wei, Kaiyan Sun, Helal Mohammed Mohammed Ahmed, Axel Künstner, Hauke Busch, Heiko Müller, Stephan Hutter, Gregor Hoermann, Longlong Liu, Xiaoqing Xie, Yahya Al-Matary, Subbaiah Chary Nimmagadda, Fiorella Charles Cano, Michael Heuser, Felicitas Thol, Gudrun Göhring, Doris Steinemann, Jürgen Thomale, Theo Leitner, Anja Fischer, Roland Rad, Christoph Röllig, Heidi Altmann, Desiree Kunadt, Wolfgang E. Berdel, Jana Hüve, Felix Neumann, Jürgen Klingauf, Virginie Calderon, Bertram Opalka, Ulrich Dührsen, Frank Rosenbauer, Martin Dugas, Julian Varghese, Hans Christian Reinhardt, Nikolas von Bubnoff, Tarik Möröy, Georg Lenz, Aarif M. N. Batcha, Marianna Giorgi, Murugan Selvam, Eunice Wang, Shannon K. McWeeney, Jeffrey W. Tyner, Friedrich Stölzel, Matthias Mann, Ashok Kumar Jayavelu, Cyrus Khandanpour

Blood (2023) 142 (25): 2175–2191.

https://doi.org/10.1182/blood.2022015752

Published: 2023

Includes: Supplemental data

Journal Articles

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2023) 142 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2023-187393

Published: 2023

Journal Articles

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 2236.

https://doi.org/10.1182/blood-2023-187273

Published: 2023

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schröder, Rudolf Trenschel, Miroslaw Markiewicz, Hélène Labussière-Wallet, Péter Reményi, Fabio Ciceri, Friedrich Stölzel

Blood (2023) 142 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2023-180816

Published: 2023

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7752–7753.

https://doi.org/10.1182/blood-2022-166023

Published: 2022

Journal Articles

Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Maximilian Alexander Röhnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Martin Bornhaeuser, Uta Oelschlägel, Malte von Bonin

Blood (2022) 140 (Supplement 1): 11824–11826.

https://doi.org/10.1182/blood-2022-165260

Published: 2022

Journal Articles

Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3454–3455.

https://doi.org/10.1182/blood-2022-166271

Published: 2022

Journal Articles

Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT

Annalisa Paviglianiti, Alberto Mussetti, Maud Ngoya, Ariane Boumendil, Zafer Gulbas, Fabio Ciceri, Francesca Bonifazi, Domenico Russo, Nathalie Fegueux, Friedrich Stölzel, Claude-Eric Bulabois, Gerard Socie, Edouard Forcade, Carlos Solano, Hervé Finel, Stephen Robinson, Silvia Montoto, Bertram Glass

Blood (2022) 140 (Supplement 1): 7645–7646.

https://doi.org/10.1182/blood-2022-169244

Published: 2022

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, Alexander D. Kulagin, Andrea Velardi, Jaime Sanz, Hélène Labussière-Wallet, Victoria Potter, Jurgen Kuball, Simona Sica, Elena N. Parovichnikova, Wolfgang Bethge, Xavier Leleu, Uwe Platzbecker, Friedrich Stölzel, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7578–7579.

https://doi.org/10.1182/blood-2022-156231

Published: 2022

Journal Articles

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Ann-Kristin Schmälter, Maud Ngoya, Jürgen Finke, Nicolaus Kröger, Friedrich Stölzel, Matthias Stelljes, Thomas Valerius, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Ali Bazarbachi, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4799–4801.

https://doi.org/10.1182/blood-2022-163788

Published: 2022

Journal Articles

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Blood (2022) 139 (1): 87–103.

https://doi.org/10.1182/blood.2020009680

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Novel Germline POT1 Variant Predisposes to Childhood Acute Myeloid Leukemia

Pia Michler, Franziska Auer, Rabea Wagener, Triantafyllia Brozou, Ulrike Anne Friedrich, Carolin Walter, Martin Dugas, Arndt Borkhardt, Friedrich Stölzel, Julia Hauer

Blood (2021) 138 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2021-150456

Published: 2021

Journal Articles

Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro

Manja Wobus, Ekaterina Balaian, Uta Oelschlaegel, Russell Towers, Kristin Möbus, Ivonne Habermann, Rebekka Wehner, Friedrich Stölzel, Triantafyllos Chavakis, Marie Törngren, Helena Eriksson, Uwe Platzbecker, Christoph Röllig, Martin Bornhäuser, Katja Sockel

Blood (2021) 138 (Supplement 1): 2596.

https://doi.org/10.1182/blood-2021-150455

Published: 2021

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2021-150281

Published: 2021

Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140494

Published: 2020

Journal Articles

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Martin Kirschner, Benjamin Rolles, MD, Martina Crysandt, Christoph Röllig, Prof., MD, Friedrich Stolzel, MD, Martin Bornhäuser, MD, Carsten Müller-Tidow, MD, Kim Kricheldorf, Margherita Vieri, PhD, Matthias Begemann, Angela Maurer, Jens Panse, MD, Susanne Isfort, Marcin Wlodarski, MD PhD, Sushree Sangita Sahoo, PhD, Tim H Brümmendorf, MD, Edgar Jost, Fabian Beier, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142815

Published: 2020

NARROW

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Impact of KMT2A -PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia

Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Novel Germline POT1 Variant Predisposes to Childhood Acute Myeloid Leukemia

Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only